American Cryostem Corp represents the values of innovation, excellence, and integrity. The company's corporate philosophy centers around advancing regenerative medicine and providing cutting-edge stem cell processing and storage solutions. With a focus on quality, American Cryostem Corp aims to deliver superior services in the field of biobanking, ensuring the long-term preservation and accessibility of valuable biological materials. Committed to customer satisfaction, they strive to maintain high ethical standards while fostering collaborations and driving advancements in healthcare. American Cryostem Corp's dedication to research, development, and their commitment to improving patient outcomes sets them apart in the industry.

American Cryostem Corp primarily operates in the United States.

American Cryostem Corp has achieved several significant milestones in its history. One of the notable achievements includes becoming a pioneer in the field of adipose tissue-based stem cell banking and research. Additionally, the company has successfully developed and implemented state-of-the-art technology and processes for the collection, processing, and cryopreservation of adipose-derived stem cells. It has also established strategic partnerships with leading medical institutions and research organizations, enabling groundbreaking advancements in regenerative medicine. Furthermore, American Cryostem Corp has expanded its service offerings globally, catering to the growing demand for stem cell storage and research.

American Cryostem Corp is a renowned company in the field of regenerative medicine. Established in 2008, it specializes in the collection, processing, and long-term storage of adipose tissue (fat) stem cells. The company's unique platform allows for the retrieval and cryopreservation of these valuable stem cells, which hold immense potential for therapeutic use. American Cryostem Corp has been dedicated to advancing the regenerative medicine industry by providing high-quality cellular-based services to medical professionals and researchers worldwide. With a focus on innovation, the company continues to contribute to the exciting and rapidly evolving field of stem cell therapeutics.

The main competitors of American Cryostem Corp in the market are [competitor 1], [competitor 2], and [competitor 3]. These companies operate in the same field as American Cryostem Corp and offer similar products/services. However, American Cryostem Corp differentiates itself by [highlighting their unique selling points, such as advanced technology, market reach, or customer satisfaction]. Overall, American Cryostem Corp competes with these companies to maintain its market position and strives to provide superior solutions for its customers.

American Cryostem Corp is primarily active in the biotechnology and healthcare industries.

The business model of American Cryostem Corp focuses on providing biobanking services and solutions for cellular therapies and regenerative medicine. The company collects, processes, stores, and distributes adipose tissue specimens from patients for research and clinical applications. American Cryostem Corp offers its services to researchers, clinicians, and pharmaceutical companies involved in stem cell-based therapies. With a strong emphasis on quality assurance and compliance, the company aims to facilitate breakthroughs in medical science while ensuring patient confidentiality and satisfaction. American Cryostem Corp's innovative business model seeks to drive advancements in the field of regenerative medicine through biobanking solutions.

The P/E ratio cannot be calculated for American Cryostem at the moment.

The P/S cannot be calculated for American Cryostem currently.

The Quality Investing for American Cryostem is 7/10.

The revenue cannot currently be calculated for American Cryostem.

The profit cannot currently be calculated for American Cryostem.

American Cryostem Corp (ACC) is an emerging company specializing in the development of stem cell technologies and products. The company offers three main services: building stem cell banks, stem cell processing, and stem cell analysis. ACC's main products are Adipostem and Hemostem cells, which are derived from fat tissue and blood. ACC is headquartered in New Jersey, USA and is listed on the NASDAQ market. Stem cell banking is one of ACC's key business segments. The company offers interested individuals the opportunity to store their own stem cells in a private bank. These stem cells can then be used for medical purposes when needed, such as in the treatment of cancer, diabetes, and other diseases. To ensure effective establishment and operation of stem cell banks, ACC has developed proprietary software called "CryoStor". This software allows for efficient management and archiving of stem cell samples. Stem cell processing is another important business segment for ACC. The company offers a range of services specialized in the processing of stem cells. The company has a state-of-the-art laboratory where this processing takes place. The company also offers training and consulting services to ensure safe and effective procedures. In addition, ACC also provides stem cell analysis services to ensure that the stem cells are of high quality and viable. The core product of ACC is Adipostem and Hemostem cells, which are derived from fat tissue and blood. These cells are used in regenerative medicine for the treatment of various diseases. Adipostem cells are primarily used for the regeneration of bone, cartilage, and muscle tissues. On the other hand, Hemostem cells can be used to stop bleeding, especially in injuries. These stem cell extracts are patented and have the potential to significantly expedite healing in treated patients. ACC aims to prove the safety and efficacy of its products through clinical trials. The business model of American Cryostem Corp is promising and has great potential in regenerative medicine. ACC's technology, products, and services contribute to improving the health and well-being of people worldwide. With well-trained staff, advanced technology, and research findings, the company ensures that the quality and effectiveness of its products and services are constantly enhanced. The company has a strong market position and is expected to continue expanding its business and playing a leading role in regenerative medicine.

American Cryostem pays a dividend of 0 USD distributed over payouts per year.

The dividend cannot currently be calculated for American Cryostem or the company does not pay out a dividend.

The ISIN of American Cryostem is US0253001046.

The ticker of American Cryostem is CRYO.

Over the past 12 months, American Cryostem paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, American Cryostem is expected to pay a dividend of 0 USD.

The current dividend yield of American Cryostem is .

American Cryostem pays a quarterly dividend. This is distributed in the months of .

American Cryostem paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

American Cryostem is assigned to the 'Health' sector.

To receive the latest dividend of American Cryostem from 4/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/17/2025.

The last dividend was paid out on 4/17/2025.

In the year 2024, American Cryostem distributed 0 USD as dividends.

The dividends of American Cryostem are distributed in USD.